This announcement marks the third foundational support pillar for Tevogen.AI, the Company’s AI initiative which aims to transform precision medicine: Microsoft Research – contributing digital ...

A team of researchers has successfully created more effective immune cells that can fight cancer without damaging healthy tissue.

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the dosing of the first patient in its Phase 1 clinical trial of CT-95, a bispecific antibody designed to target ...

Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more ...

A team of researchers from the Rice Biotech Launch Pad at Rice University has developed an implantable "cytokine factory" that safely triggers potent immune responses against hard-to-treat cancers, ...